In fact, Barraud et al. showed that FK866, a NAMPT inhibitor, could decrease intracellular NAD+ level and cell viability of patient-derived pancreatic cancer cell lines and that their sensitivity to FK866 was directly related to their NAMPT expression levels [11]. The gene discussed is NAMPT; the disease is pancreatic neoplasm.